Print

IAVI A001

A Phase 1 Randomized, Placebo-Controlled, Double-Blind Dose-Escalation Trial to Evaluate the Safety and Immunogenicity of tgAAC09, a Gag-PR-RT AAV HIV Vaccine

Trial Details:

I Completed
IAVI Targeted Genetics Corporation Children's Hospital of Philadelphia Nationwide Children's Hospital December 01, 2003
tgAAC09 AAV2 Gag-PR-RT C
tgAAC09 Viral Vector - Adeno-associated Virus
Belgium, Germany, India 80
NCT00482027
http://www.targen.com/ http://www.clinicaltrials.gov/ct2/show/NCT00482027?term=a001+AND+hiv&rank=1